Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information
MOON SHOTS PROGRAM
The prostate is a walnut-size gland in the male reproductive system that is fueled by male hormones called androgens. Prostate cancer develops when cells within this gland begin to grow uncontrollably. It's the second leading cause of cancer deaths in men in the United States. While many treatment options exist, little is known about the disease progression of prostate cancer. Because of this, many men will receive unnecessary treatment, while others will undergo treatment that is not aggressive enough.
As a part of the nation’s leading cancer hospital, the Prostate Cancer Moon Shot® team incorporates the knowledge and experience of clinicians and researchers from multiple disciplines and platforms. Together, we are working to bring cures to more patients by more fully understanding the biology of the disease and transitioning standard treatment toward curative approaches.
Ana Aparicio, M.D.
Associate Professor, Department of Genitourinary Medical Oncology
Christopher J. Logothetis, M.D.
Chair, Genitourinary Medical Oncology
Nicholas Navin, Ph.D.
Professor, Department of Genetics
Your gift can help propel innovative clinical research and trials aimed at improving outcomes for prostate cancer patients, some of whom are facing the current incurability of their disease.
Aggressive variant prostate cancer (AVPC) is a subtype of prostate cancer that is not responsive to androgen receptor or immune checkpoint inhibitors. Ana Aparicio, M.D., is working to better understand how oncogenic lesions and changes in tumor cell identity contribute to the development of this subtype and to leverage this biology to develop novel and effective combination therapies.
Learn moreAlthough metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at MD Anderson.
How the Prostate Cancer Moon Shot aims to improve outcomes, save lives
Prostate Cancer Moon Shot co-leader Christopher Logothetis, M.D., discusses the challenges of treating prostate cancer with immunotherapy and MD Anderson’s ongoing efforts to improve the lives of patients with the disease.
Researchers find abundant cytokine crowds out helper T cells crucial to treatment, an explanation as to why immunotherapy has been largely unsuccessful against prostate cancer bone metastases. This research also points to a possible combination of anti-CTLA-4 and anti- TGF-β that could reverse the resistance.
How single-cell analysis is revolutionizing prostate cancer research
Associate Professor Nicholas Navin, Ph.D., has pioneered a way to analyze the DNA of individual cancer cells. Now, he is collaborating with the Prostate Cancer Moon Shot team to use single-cell analysis to study how prostate cancer cells respond to different treatments—and allowing patients to forego invasive biopsies in the process.
